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              PREVALENCE OF CARDIAC AUTONOMIC NEUROPATHY 
IN TYPE 2 DIABETIC PATIENTS 
 
BACKGROUND: Diabetes mellitus is a global epidemic .Prevalence of 
diabetic cardiac autonomic neuropathy is high and it carries a high mortality 
rate. Early diagnosis of cardiac autonomic neuropathy helps to identify 
individuals at risk and prioritize the management. 
 
AIMS OF THE STUDY: To study the prevalence of cardiac autonomic 
neuropathy in Type 2 diabetic patients by assessing the individuals by              
(a) Standard autonomic testing & (b) Ansiscope . 
 
METHODS: Patients with Type 2 diabetes from FEB 2013 to DEC 2014 were 
included in the study. Patients were subjected to symptom analysis, clinical 
examination and laboratory investigations. Eligible cohorts were subjected to 
standard autonomic testing and testing with Ansiscope. Standard autonomic 
testing includes (a) Assessing heart rate variability with deep breathing, 
valsalva, supine to standing position.(b) Assessing blood pressure variability 
with  supine to standing position. Patients were categorised based on Ewing’s 
criteria for CAN. 
RESULTS: 19% (n=16)of the study group individuals were newly detected 
T2DM. Among them 11 individuals 68.8% were CAN positive by ansiscope and 
81.2 % (13 subjects) by conventional method. 50 individuals were diabetic for a 
duration 1-5 years. Among them 82% (41 individuals) and 88%(44 subjects) 
tested positive for autonomic dysfunction by ansiscope and conventional 
method respectively. 18 subjects who were diabetic for more than 5 years tested 
100% positive for autonomic dysfunction by both the methods.  
CONCLUSION: The prevalence of cardiac autonomic neuropathy is extremely 
high among diabetics. Poor blood sugar control is significantly associated with 
CAN . Also individuals who are unaware of the complications of diabetes have 
shown a significant association with autonomic dysreflexia. Early screening, 
early diagnosis, proper education of patients and strict glycemic control help in 
the arrest of progression of  Cardiac Autonomic Neuropathy in Type 2 diabetic 
population. 
 
KEYWORDS: 
Diabetes, cardiac autonomic neuropathy, Ansiscope, autonomic testing, 
Ewing’s criteria. 
 
 
 
1 
INTRODUCTION 
 
DIABETES: A CHALLENGE OF 21
st
  CENTURY 
          Change in the lifestyle of people along with globalization in the 
past century has increased the incidence of diabetes. Findings of a report 
by Ramachandran et al has proved (1)urbanization of India causing a 
high prevalence of diabetes.It has increased from 13.9 in 2002 to 18.2 in 
2006 in urban areas. The rural area also showed a increase in prevalence 
from 6.4 in 2002 to 9.2 in 2006. According to International Diabetic 
Federation diabetes atlas, (2)India is next only to china hosting the high 
number of people with diabetes. The number of people with diabetes is 
expected to increase from 65.1 million in 2013 to 109 million in 2035 in 
India .. Indians develop diabetic complications at an early age. This 
results in increase in mortality and morbidity among Indians. Despite a 
high prevalence of diabetes in South -east  Asian countries only 5 % of 
the global health care cost goes towards diabetes care.  Prevention of  
complications associated with diabetes is achieved by primary 
prevention  by modifying risk factors such as insulin resistance and 
obesity.(4)      
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Type 2 diabetes is a disorder characterized by insulin  resistance, 
relative decrease in insulin secretion  and hyperglycemia. Environmental 
and genetic factors play a role in the development of diabetes  
Diabetic neuropathy a set of clinical syndrome sometime silent 
and undetected, may be single or combined with signs which are non 
specific, insidious and slow and often diagnosed by exclusion.   
Neurologic complications occur equally in all types of diabetes – type I, 
type II and all other types of diabetes(19). 
One fourth of patients attending diabetes clinic had diabetic 
neuropathy based on the symptoms present. A simple clinical 
examination like testing for ankle jerk or vibration test revealed a 
positive test in 50% of individuals. A more sophisticated test for 
autonomic neuropathy showed a 90% incidence of neuropathy in 
diabetic patients at diagnosis (21) 
Diabetic neuropathy is the most common cause of hospitalization 
than other known cause of complications (22). So early diagnosis of 
cardiac autonomic neuropathy by using simple non invasive 
investigation – heart rate variability using ECG helps in the 
identification of  individuals at risk. 
This study aimed at assessing the prevalence of Cardiac 
Dysautonomia in type 2 diabetic individuals using conventional testing 
methods and by using mathematical instrument- Ansiscope  
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AIMS OF THE STUDY 
 
1. To study the prevalence of cardiac autonomic neuropathy in Type 
2 diabetic patients by assessing the individuals  by  
          a. Standard autonomic testing and  
          b. Ansiscope  
at Government Stanley Medical College and Hospital, Chennai. 
2. Early diagnosis of cardiac autonomic neuropathy helps to identify 
individuals at risk and prioritize the management. 
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REVIEW OF LITERATURE 
 
DIABETES:-  A GLOBAL TSUNAMI  
Type 2 diabetes is a disorder characterized by insulin resistance, 
relative decrease in insulin secretion  and hyperglycemia. Environmental 
and genetic factors play a role in the development of diabetes.  
CLINICAL RISK FACTORS  
Individuals whose are mother is a diabetic has a 5-6 fold 
increased risk of developing diabetes(5,6). Family history in a first 
degree relative increases the risk by about 2 to 3 times. Asians or 
African Americans  are more susceptible than whites.(7) Obesity is a 
major risk factor in type 2 diabetes as it increases peripheral insulin 
resistance (8) 
Life style  factors like decreased physical activity, high fat diet, 
smoking ,alcohol and obesity play a pathogenic role (9) 
Smoking has a definite relationship(10) with development of 
diabetes. Sleep duration  has a definite relationship  to the development 
of diabetes.(13) Both  inadequate sleep of less than  5 to 6 hrs /day and  
excess sleep of more than 8 hrs /day  is associated with increased risk of 
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diabetes. Disruption of sleep produces low melatonin secretion which 
increases the risk of developing diabetes.(14)  
Dietary patterns like increased intake of sweets ,high fat dairy 
products, red meat, processed meat are associated with increased risk  
(15)  Sugar sweetened soft drinks , producing weight gain, deficiency of  
vitamin D, Selenium(16)chromium(17) have a role in the development 
of diabetes. Women who had gestational diabetes, patients with heart 
failure, MI, hyperuricemia, polycystic ovary syndrome are associated 
with increased risk of becoming diabetic.  
ADA Criteria for the diagnosis of diabetes (18)        
1. HbAIC >=6.5 %     OR 
2. Fasting plasma glucose >= 126 mg/dl . (Fasting  is taken as  no 
energy  intake for 8 hours at least )  OR 
3. 2hour  plasma glucose >=200 mg/dl  in an OGTT.  ( to be done 
using a  75 g glucose load) OR  
4. In a patient with classic symptoms of hyperglycemia,  a random 
plasma glucose >= 200 mg/dl     
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DIABETIC NEUROPATHY 
Ziegler et al. in a cohort of type I and Type II diabetic patients 
showed that type I diabetic was associated with 25% and type II diabetic 
with 35% risk of autonomic neuropathy using variability of the heart 
rate and spectral analysis of the R-R interval. (23) 
San Antonio convention (24) has classified neuropathy into                                              
1.  Sub clinical neuropathy  - detected with electro diagnostic testing   
a. nerve conduction studies   
b. abnormal quantitative sensory test    
c. quantitative autonomic test 
2.  Diffuse  clinical neuropathy  
a.   distal symmetric sensory motor neuropathy  
b.    autonomic   neuropathy. 
3.   Focal syndrome 
a. Mononeuropathy-median, ulnar, peroneal nerve  involvement. 
b. Cranial mononeuropathy  - VII, III, IV, VI  cranial nerves 
involvement 
c. Mononeuropathy multiplex  
d. Plexopathy  
e. Polyradiculopathy 
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NATURAL HISTORY OF NEUROPATHY 
Two distinct groups of neuropathies exists  
1. Sensory and autonomic neuropathies that keeps progressing  
2. Focal and acute painful neuropathies  that tends to regress 
Poor blood sugar control is the major risk factor for progression of 
neuropathies. (25) 
There is a steady rate of deterioration of   Nerve Conduction 
Velocity(NCV)  at the rate of 1 m/sec/yr in type 2 diabetics after 
diagnosis . In type 2 diabetics peripheral neuropathy may be present 
even at diagnosis (26) or may precede the diagnosis of diabetes. 
Distal symmetric sensory motor polyneuropathy is the most 
common type in diabetics. (27)Small fibre involvement occurs earlier. 
Patients present with positive symptoms like pain and burning sensation. 
Later in the course of disease  numbness and  paresthesia  may develop . 
Large fibre involvement is  characterized by  ulcers and gangrene of the 
foot.  
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Clinical screening test for diabetic peripheral neuropathy 
VIBRATION TESTING :  128 Hz tuning fork is used for testing. It  is 
tested over the dorsum of great toe and other bony prominences. Graded 
tuning fork  may also  be used.                                                                                                                
 Biothesiometer is an electronic tuning fork which based on the 
voltage used  allows  vibrations to be adjusted .  The lowest voltage that 
a normal person can sense is 6 volts in individuals less than 30 yrs  and 
20 volts in age 75 yrs and above. The lowest voltage perceived is called 
vibration perception threshold 
PRESSURE SENSATION TESTING:  10 g monofilament  also called 
Semmes Weinstein monofilament  (29)  is used to assess the pressure 
sensation. The monofilament is placed at right angles to the skin on the 
plantar surface of the foot. Pressure is increased until the filament 
buckles indicating a 10 g pressure applied. Sites to be tested are  plantar 
surface of great toe , metatarsal heads, heel, dorsum of great toe . 
PAIN /TEMPERATURE TESTING: pin prick sensation and hot cold 
sensation to be tested  
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NERVE CONDUCTION STUDIES                                                                   
Demonstrates axonal degeneration and decrease in compound 
muscle action potential. Electrophysiological abnormalities are 
characteristic of large fibre  neuropathy . 
SMALL  FIBRE AND  LARGE  FIBRE NEUROPATHY  
SMALL FIBRE NEUROPATHY 
1. Pain – superficial and burning type  
2. Abnormal  warm sensation  
3. Abnormal autonomic function like dry skin , cold feet , decreased 
sweating , gastric and genitourinary disturbances . 
4. Normal muscles strength and deep tendon reflexes  
5. Nerve conduction studies – normal                                                
LARGE FIBRE NEUROPATHY 
1. Abnormal vibration and joint position sense  
2.  Decreased / absent deep tendon reflexes  
3. Deep , vague , dull , crushing or cramp like pain  
4.  Numbness , cotton wool sensation feet  
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5.  Sensory ataxia  
6.   Small muscle wasting of feet  
7.  Hammer toes , pes equinus deformity  
8.  Warm feet due to increased blood flow  
CLINICAL FEATURES OF DIABETIC AUTONOMIC 
NEUROPATHY    
Cardiovascular System  
- Resting tachycardia 
          - Orthostatic hypotension 
          - Exercise intolerance 
          - Silent myocardial ischemia 
Gastro Intestinal System  
          - Constipation 
          - Diarrhea 
          - Esophageal dysmotility 
         - Gastroparesis diabeticorum 
          - Fecal incontinence 
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Genitourinary System  
       - Erectile dysfunction  
       - Retrograde ejaculation 
       - Neurogenic bladder (diabetic cystopathy) 
       - Female sexual dysfunction (e.g., loss of vaginal lubrication) 
Metabolic 
- Hypoglycemia-associated autonomic failure 
- Hypoglycemia unawareness 
Sudomotor 
- Anhidrosis 
- Heat intolerance   
- Dry skin 
- Gustatory sweating 
Pupillary 
- impairment of pupillomotor function impairment decreased 
diameter of dark adapted Pupil  
- Argyll-Robertson pupil 
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The differential diagnosis of DAN involves  excluding the following 
conditions: 
a. Addison’s disease and hypopituitarism 
b. Pheochromocytoma 
c.  idiopathic orthostatic hypotension  
d. Shy Drager syndrome - multiple system atrophy with autonomic 
failure 
e. Hypovolemia 
f.  Medications -  anticholinergic, sympatholytic effects with 
insulin, vasodilators 
g. sympathetic blockers 
h. Peripheral autonomic neuropathies  idiopathic autonomic 
neuropathy, amyloid neuropathy. 
ASSOCIATION OF PERIPHERAL AND CARDIAC 
AUTONOMIC NEUROPATHY 
Peripheral neuropathy is classified as small and large fibre 
neuropathy. Small fibre neuropathy presents as painful neuropathy 
where as large fibre affection presents as painless neuropathy and foot 
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ulcers.painful small fibre neuropathy is associated more with autonomic 
dysfunction.  (35) 
Llunch et al has studied autonomic dysfunction in type 1 diabetes. 
Frequency of autonomic dysfunction is more in  type 1 diabetics and the 
prevalence increases with presence of peripheral neuropathy and 
increased duration of diabetes(36) 
Another study conducted by rajiv et al has demonstrated that 
painful distal sensory neuropathy is associated with greater autonomic 
dysreflexia than painless neuropathy. CAN was assessed by frequency 
domain spectral analysis of HRV and somatic neuropathy by detailed 
neurophysiological testing. (37) 
Pain and autonomic sensation is carried via small myelinated and 
unmyelinated nerve fibres as against vibration and touch carried by large 
fibres. Hence small fibre neuropathy is associated with painful DSN and  
Autonomic involvement.  
Important clinical implication is that patients presenting with 
painful DSN should be assessed for autonomic dysfunction also for 
early detection. 
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DIABETES AND HEART 
 
1. DIABETIC DYSLIPIDEMIA 
Atherogenic dyslipidemia is characterized by  
 Increased VLDL 
 increased small LDL 
 decreased HDL  
This triad of lipid abnormalities is atherogenic and produces premature 
CHD. Most of these patients are insulin resistant.(38) 
2. HYPERTENSION  
Hypertension is a independent risk factor for CAD, stroke, 
nephropathy(39) 
Some studies have shown a positive association of HT with 
insulin resistance(40) 
3. PROTHROMBOTIC STATE 
Patients with metabolic syndrome are prothrombotic. (41) 
Patients with insulin resistance have raised levels of fibrinogen, 
plasminogen activator inhibitor – 1(42) 
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4. CARDIAC FAILURE 
diabetic patients have increased incidence of heart failure  with 
preserved systolic function as shown in Framingham heart study. 
Possible mechanisms 
 Atherosclerosis 
 Obesity 
 Persistent hyperglycemia 
 Sustained hypertension 
 Microvascular alterations 
 Altered myocardial proteins 
Mortality rates of diabetics with cardiac failure is high (43) 
5. DIABETIC CARDIOMYOPATHY 
Ventricular dysfunction that occurs per se in diabetics in absence 
of associated ischemia or HT. Probable mechanisms could be altered 
myocardial metabolism, microangiopathy. 
6. CORONARY ARTERY DISEASE 
Both type 1 and type 2 diabetes are independent risk factors for 
CHD.(44) premature aherosclerosis and associated metabolic syndrome 
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play a role. Due to associated cardiac denervation and dysautonomia 
silent myocardial infarction is common. (45) 
7. CARDIAC AUTONOMIC NEUROPATHY 
CAN as outlined elsewhere is associated with exercise 
intolerance, intraoperative lability, postural hypotension and silent 
myocardial infarction.  
CARDIAC AUTONOMIC NEUROPATHY 
Anatomy  
Sympathetic nervous system  
Preganglionic fibres arise from lateral column of spinal cord. 
They synapse in the lower three cervical and upper three thoracic 
ganglion. The post ganglionic fibres forms the deep cardiac plexuses. 
They travel along arteries and are formed in the outer wall of blood 
vessel, atria, ventricles , SA- AV node and cardiac myocytes.  
Parasympathetic nervous system(PNS) 
PNS originates from medial medullary sites – nucleus ambiguous, 
dorsal motor nucleus of vagus, nucleus tractus solitarius. These are 
under control of hypothalamus. The vagal nerve,  main parasympathetic 
innervations of heart exits from the medulla and enters the carotid 
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sheath penetrates the chest and synapses within the chain of ganglion 
located in the cardiac fat pads and the post ganlionic fibres supply the 
heart mainly SA and AV nodes. While the atrial musculature is also 
innervated by vagal efferents ventricular myocardium Is only sparingly 
innervated. 
Sympathetic activation  
Mediated by alpha receptors- causes  
1. Positive chronotrophic effect( increased heart rate) 
2. Positive inotrophy (contractility) 
3. Positive dromotrophy ( conduction velocity via B1 receptor)   
4. Increase lusitropy (rate of relaxation)  
Parasympathetic activation  
Mediated by muscuranic receptors causes  
1. Negative chronotrophy and dromotrophy 
2. Negative inotrophy and lusitrophy in atria  
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Sympathetic and parasympathetic interaction  
In the resting state vagal tone predominates. Efferent vagal 
activation inhibits sympathetic activation. During exercise sympathetic 
tone overtakes.  
Chronic hyperglycemia produces distal dying back neuropathy in 
peripheral nerves. Similar to this the longest autonomic nerve vagus is 
affected. Hence CAN in diabetes is characterized by early affection of 
parasympathetics and compensatory augmentation of sympathetic tone. 
Later in the course parasympathetic imbalance develops. (46) 
CLINICAL MANIFESTATIONS  
1. Exercise Intolerance  
Kahn et al studied persons with and without CAN. He showed a 
decreased response in blood pressure and heart rate in individuals with 
CAN. (48) 
Roy et al  showed decreased cardiac output with exercise in 
persons with CAN(49)  
Exercise induced heart rate increase and maximum heart rate 
increase achieved with exercise is inversely related to the severity of 
CAN  
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Cardiac autonomic dysreflexia produces reduced exercise 
tolerance, decreased cardiac ejection fraction, systolic and diastolic 
dysfunction. 
2. Cardiovascular Liability During Intraoperative Period  
Burgos et al described need for increased vasopressor support in 
diabetics with autonomic dysreflexia(50) 
Kitamura et al has shown increased hypothermia during  intra 
operative period in patients with CAN.(51)  
Sobotka et al has demonstrated decreased hypoxia related 
ventilatory drive in individuals with CAN. (52) 
Patients with CAN anaesthesia related vaso dilatation is not 
compensated by autonomic response of vaso constriction and increase in 
heart rate.  
Intraoperative reduction of core temperature causes decrease in 
metabolism of drugs and impairs healing of wounds.  
3. Orthostatic Hypotension 
A decrease in systolic pressure of more than 20mmhg and 
diastolic of more than 10 mmhg from supine to standing posture is 
called as orthostatic hypotension  
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1. In response to change in posture there is stimulation of 
sympathetic nervous system  by activation of barorecepyor reflex 
and  there is release of norepinephrine which causes splanchic 
vasoconstriction and a raise in blood pressure . in diabetics 
efferent sympathetic are damaged and blunting of this response 
associated with a decreased total vascular resistance produces a 
postural fall in blood pressure . 
2. Also associated extravascular fluid retention due to cardiac and 
renal failure produces a reduction of blood volume . 
3. Insulin per se  has hypotensive action  
4. Splanchnic vasodilation associated with post prandial state  
5. decreased cardiac stimulation and decreased cariac output has a 
role. 
Symptomatology  
a. light headedness , black outs, presyncope 
b. dizziness, easy fatigue, blurring of vision , neck pain  
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4. Silent Myocardial Infarction  
Ambepityia et al had studied perception of angina pain threshold 
in persons with and without diabetes . He had also assessed the 
autonomic function tests in these individuals. He had documented a 
decreased angina pain perception in persons with diabetes and also had 
correlated this association with presence of autonomic neuropathy in 
these individuals . (53) 
Vinick et al has documented a definitive relation between CAN 
and silent MI (54) 
In DIAD study (detection of ischemia in asymptomatic diabetics) 
1123 patients were studied and CAN was found to be a strong predictor 
of silent MI and cardiovascular deaths  in diabetics . (55) 
Detection of CAN is essential in diabetics as they continue to 
exert despite developing myocardial ischemia as they do not perceive 
the pain.  
Causes  
1. Cardiac denervation due to autonomic nervous system 
involvement  
2. Decreased sensitivity to pain perception  
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3. Altered pain thresholds  
4. Impaired neuronal activation and signal transmission from 
thalamus to frontal cortex 
Diabetics with CAN present with following atypical features like 
cough, dyspnoea, unexplained Fatigue, atypical chest pain,only ECG 
changes,nausea /vomiting, edema.haemoptysis 
a. Diaphoresis 
b. Arrhythmias  
c. Confusion  
A high index of suspicion needed by treating physician  
Also in type 1 diabetic patients presence of CAN is associated 
with early development of diastolic dysfunction and cardiomyopathy 
(56) 
5. Increased Risk of Mortality  
Ewing et al has documented a 27 % increase in 5 year mortality 
rate in diabetic patients with CAN as against 15 % increase in mortality 
in those without. Most deaths were due to renal failure and sudden 
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cardiac death. Patients with CAN and gastric autonomic symptoms and 
orthostatic hypotension had worse prognosis.  
O’Brein had noted a mortality rate at 5 year in patients with 
autonomic dysreflexia as 27 % and those without as about 8% (57) 
Rao et al has documented CAN as a independent risk factor for 
mortality rate prediction % (58) 
Two population based studies, namely Orchard et al and Hoorn 
study which assessed association of CAN and mortality in type 1 and 
type 2 diabetic population respectively have shown significant 
association between the two. (59)CAN is also associated with major 
cardiovascular end points like cardiac failure, myocardial infarction , 
arrhythmias, angina pain and need for revascularization procedures .  
Causes of high mortality associated with CAN  
a. Poor hypoxia induced respiratory stimulation  
b. Increased sympathetic tone and lack of nocturnal dipping of blood 
pressure 
c. Disturbance in circadian pattern of sympathovagal response is 
associated with left ventricular hypertrophy  
d. Lethal arrhythmias induced by asymptomatic ischemia/infarction  
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e. QT prolongation associated with autonomic dysreflexia 
predisposes to various rhythm disturbances. 
f. Increased incidence of LV dysfunction and cardiac failure in 
diabetics with neuropathy  
g. Hypoglycemic unawareness  decreases threshold for arrhythmias. 
h. Hypoglycemia affects autonomic nervous system in diabetics   
6. CAN associated with increased mortality in post MI patients  
Autonomic dysfunction  predisposes to various arrhythmias post 
MI. Fava et al has documented this (60) 
Katz et al has tested 1 min HRV with deep breathing in post MI 
patients to assess CAN  is a good predictor of mortality post MI   (61)  
7. Stroke 
Incidence of ischemic stroke is high in diabetics associated with 
cardiac dysreflexia and is an independent predictor of cerebrovascular 
events.  
Toyry et al has demonstrated this association in diabetic 
population (62) 
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NATURAL HISTORY OF PROGRESSION OF CAN  
a. Usually parasympathetic dysfunction precedes sympathetic but 
this may not be always true. 
b. Autonomic dysfunction can be detected at diagnosis in type 2 
diabetes.(63) 
c. Age, type of diabetes and to some extent duration of diabetes do 
not correlate with the development of CAN.(64) 
d.  Pivotal role in development and progression of CAN is mainly by 
the glycemic control  in the patients (65) 
e. Intense glycemic control delays the onset and also delays 
progression of autonomic dysfunction(66) Orthostatic 
hypotension due to sympathetic derangement is a late 
manifestation  
f. Diabetic nephropathy is strongly associated with CAN  (67) 
g. Type 1 and type 2 diabetes may have a difference in rate of 
progression  
h. Mortality rates due to CAN is more in type 1 diabetics than type 2 
as there is a long latent period  before diagnosis in type 2 . 
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PATHOGENESIS  
Free radicals -a free radical is a species which has one or more 
unpaired free electron in its orbit.  
Mechanism of generation of oxygen free radicals 
Electron transfer reactions like hydroxyl radicals , superoxide 
anion radical, lipid alkoxyl and peroxyl radical and hydrogen peroxide 
generate free radicals. 
Energy transfer reactions like triplet carbonyl compounds and 
singlet oxygen are also involved in generation of free radicals  
Hyperglycemia Induced Mitochondrial Superoxide Production 
During electron transfer in respiratory chain a proton gradient is 
created by extrusion of protons into inter membrane space of 
mitochondria  
This gradient stimulates ATP synthase. In diabetes with high 
intracellular glucose concentration, more glucose is oxidized via citric 
acid cycle and electron donors like NADH,FAD H2 gets used up. After 
a critical threshold the electron transfer inside complex 3  gets blocked. 
This process produces electron to get backed-up to co enzyme Q which 
donates electron to oxygen producing superoxide anion.  
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Hyperglycemia activates other pathways like redox changes, 
NADPH oxidases and uncoupled eNOS  gets amplified and produce 
superoxide. 
Hyperglycemia Induced Mitochondrial Superoxide Production- 
Activates Other Pathways By Inhibiting GAPDH 
Intracellular hyperglycemia reduces the glycolytic enzyme 
GAPDH. This causes other glycolytic intermediates to increase  
1. High levels of glyceraldehydes 3 phosphate – glycolytic 
metabolite activates following two pathways.  
a.  AGE pathway - glyceraldehydes 3 phosphate is the source for 
AGE precursor methyl glyoxal.  
b. Classic protein kinase C (PKC)pathway : glyceraldehydes 3 
phosphate is the source for diacyl glycerol which is the activator 
of PKC pathway  
2. Levels of fructose 6 phosphate increase which is a glycolytic 
metabolite activates hexose amine pathway to form UDP- 
GlcNAc. 
3. GADPH inhibition also increases the intracellular glucose level 
which enters polyol pathway.  
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a. Sorbitol is formed from glucose by the enzyme aldolase reductse 
consuming NADPH.  Increased sorbitol is neurotoxic causing 
Schwann cell damage by increasing cell   osmolarity. 
b. Depletion of NADPH in the above process decreases intracellular 
myoinositol which interfere with cellular metabolism.  
 
Mechanism of hyperglycemia induced cellular damage 
Cellular injury due to increased reactive oxygen species  
1. Oxygen free radicals attack the iron – sulfur moiety of enzymes 
and proteins and inhibit them. the proteins more susceptible for 
inhibition are complexes I-III  of electron transfer chain, biotin 
synthase and aconitase of citric acid cycle. 
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2. Lipids in membranes of  mitochondria, plasma and endoplasmic 
reticulum undergoes peroxidation. The end products of this 
process- lipid peroxides are toxic to the cell. 
3.  Proteins and nucleic acid in the cells undergo peroxidation and 
nitrosylation which are toxic to the cell. 
4.  Oxidative modification of various transcription factor causes 
reduced expression of anti apoptic proteins like Bcl -2 and 
increase in proapoptic proteins. 
5.  Oxidative damage of DNA especially in non dividing cells like 
neurons affect axonal transport and signaling resulting in loss of 
function of neurons.  
NRF2 and Oxidative Stress  
NRF2 is a transcription factor protects against oxidative stress. 
NRF2 expression is down regulated in diabetic nerves. DRG neurons are 
protected from free radical injury via NRF2 activation. Hence 
hyperglycemia induced down regulation of NRF2 makes Schwann cells 
and DRG more susceptible to oxidative stress. 
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Role Advanced Glycation End Products in the Pathogenesis of 
Diabetic Neuropathy  
AGEs  
AGE are heterogenous compounds which are formed by non 
enzymatic glycation and oxidation of proteins and or lipids with aldose 
sugars. 
Formation of AGE  
Aldehyde of glucose combines with amino acid side chain and 
forms covalent bond which is labile. Early glycation produces Schiff 
basis which are reversible. These undergo further glycation and amadori 
rearrangement to produce irreversible AGE products.  
EXAMPLES: Pentosidine, Glycated HbA1C, N-carboxy methyl lysine,  
Methylglyoxal 
 
Formation  of advanced glycation end products 
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Receptor for Age (RAGE) 
RAGE belongs to immunoglobulin receptor super family. They 
are expressed minimally in normal non diabetic tissue and vessels. 
Chronic hyperglycemia produces more AGE products which by 
feedback mechanism up regulates RAGE expression. RAGE stimulation 
produces pro inflammatory response. 
AGE on Function of Extracellular Tissue  
1. AGE produces cross linking of elastin and type I collagen there 
by producing increase stiffness of vessels .  
2. AGE interaction via RAGE decreases binding heparin sulfate, a 
proteo glycan in the vessel wall to the basement membrane 
producing a procoagulant state. 
3. Glycation of LDL decreases nitrous oxide thereby decreasing 
vaso dilatation. 
4. Glycated LDL decreases clearance and uptake of LDL producing 
a pro atherogenic state promoting smooth muscle cell 
proliferation and atheroma formation in endo neurial vessels  
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AGE on Function of Intra Cellular Milieu 
1. Glycation of FGF affects vascular homeostasis. 
2.  AGE induced stimulation of monocytes and endothelial cells 
causes increased expression of E-selectin,VEGF,VCAM-1, 
ICAM-1, other pro inflammatory cytokines like IL1, IL6,TNF–A, 
RAGE.  
Role of AGE in Diabetic Neuropathy 
1. AGE/RAGE induce oxidative stress that increases glycosidation 
products like pentosidine 
2. Upregulation of nuclear product NF- kappa B and various pro 
inflammatory genes alter neurological function. 
3. Atherosclerotic endo neureal vessels produces ischemic nerve 
damage.  
4. Hyper glycemia induced AGE causes segmental demyelination of 
peripheral nerves. 
5. AGE alters cyto skeletal proteins of axons like tubulin,actin, 
neuro filament andproduces atrophy of axons and degeneration.  
6. Glycation of laminin produces reduced axonal regeneration.  
7. Endo neurial deficiency of nitrous oxide affects microvasculature. 
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POLYOL PATHWAY  
Peripheral nerves uptakes glucose in a noninsulin dependant 
manner. In hyperglycemia high glucose in the nerves enter polyol 
pathway. 
Two enzymes are involved in the above pathway. 
a. Aldose reductase(AR)- in the presence of co factor NADPH 
reduces glucose to sorbitol. 
b. Sorbitol dehydrogenase (SDH) – in the presence of cofactor NAD 
+ forms fructose from sorbitol. 
1. Depletion of NADPH by AR decreases the formation of 
myoinositol. Myoinositol depletion alters phosphoinositide 
metabolism thereby reducing Na+K+ ATPase activity and 
reducing nerve conduction velocity.  
2. Depletion of NADPH causes reduction of nitric oxide and inhibits 
vascular relaxation producing chronic ischaemia. 
3. NADPH is a cofactor for glutathione reductase and hence its 
depletion produces oxidative injury. 
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4. Sorbitol oxidation by SDH produces NADH from NAD+. NADH 
acts as a substrate for NADH oxidase to produce  ROS. 
5. Fructose formed is converted to 3 deoxy glucasone and fructose 3 
phosphate. These are extremely potent nonenzymatic glycation 
agents. AGE acts via RAGE causing oxidative stress.  
PROTEIN KINASE C PATHWAY 
Hyperglycemia increases diacyl glycerol which activates PKC. 
Active PKC increases expression of TGF B and other pro inflammatory 
cytokines which produces oxidative damage of the diabetic nerves.  
HEXOSAMINE PATHWAY  
Fructose 6 phosphate is converted to glucosamine 6 phosphate by 
hexosamine. Increased flux through this pathway causes PKC activation 
and inflammatory cytokines over expression.  
ROLE OF ISCHAEMIA IN THE PATHOGENESIS OF 
DIABETIC NEUROPATHY  
Nerve- Vascular Supply   
A. Intrinsic system- micro vessels within endoneurium  
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B. Extrinsic system – nutritive arteries, arterioles and epineurial 
vessels  
There are extensive anastomosis between the two systems thereby 
preventing neural ischaemia.  
Diabetic nerve tissues demonstrate many endoneurial 
abnormalities of micro vessels like     
a. Thickening of basement membrane  
b. Proliferation of smooth muscle  
c. Swelling and proliferation of endothelial cell  
d. Platelet thrombi 
Pathways involved in ischaemic nerve damage  
a. AGE induce various cytokine and growth factors from 
macrophage resulting in atheroma and obstruction of vessels  
b. Hypoxic insult further stimulate oxygen free radical production, 
lipid peroxidation thrombaxane increase decrease in prostacyclin 
producing vasoconstriction 
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c. Polyol pathway results in production of sorbitol which affects 
prostcyclin production and sodium pumpand depletion of 
NADPH thereby decreasing NO production. 
d. Nerve Growth Factor(NGF) are produced in the peripheral organs 
and reach the cell bodies of neuron by retrograde axon transport. 
NGF are essential for nervous system regeneration and endurance. 
Chronic hyperglycemia blunts the above response.  
CLINICAL SIGNS OF CAN  
HRV –Impaired 
a. Earliest sign  
b. Beat to beat variation is a function of integrity of sympathetic and 
parasympathetic activity. 
c. Heart rate varies in response to normal respiration producing 
sinus arrhythmias which disappears with ANS dysfunction  
Resting Tachycardia 
a. Parasympathetic dysfunction produces a state of increased 
sympathetic tone which produces a increment of heart rate at rest  
more than 100/ min  
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b. But other causes like thyrotoxicosis, stress, exercise, heart failure, 
anaemia to be ruled out. 
c. A fixed heart rate despite stress exercise indicates CAN. 
Cardiac Stress Testing  
Poor Exercise tolerance can be assessed by stress test. Individuals 
with CAN have decreased heart rate, BP, and cardiac output  with 
exercise. 
Non Dipping BP at Night  
           With sleep, in normal persons parasympathetic tone predominates 
hence heart rate and BP falls at night. But in presence of autonomic 
dysfunction sympathetic tone predominates and these persons are 
nocturnal nondippers.  
These individuals develop concentric left ventricular hypertrophy.  
Orthostatic Hypotension  
a. Late manifestation  
b. Damage to sympathetic vasomotor system. 
light headedness, black outs, presyncope, dizziness, easy fatigue, 
blurring of vision , neck pain are the clinical presentations. 
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TESTING OF CARDIOVASCULAR AUTONOMIC 
DYSFUNCTION  
In 1970, Ewing et al put forth 5 noninvasive tests to assess the 
sympathovagal response (74) other causes of autonomic dysfunction like 
alcohol intake, drugs like diuretics, insulin, antidepressants, 
vasodilators, aspirin, age use of caffeine, exercise , smoking to be taken 
into consideration for the validity of the test. 
Test for parasympathetic system assessment  
a. Heart rate response to deep breathing  
b. Heart rate response to valsalva maneuver 
c. Heart rate response to standing  
Test for parasympathetic system assessment  
a. Blood pressure response to standing  
b. Blood pressure response to sustained hand grip 
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Tests for detection of cardiac dysautonomia  
 A. healthy subject B. diabetic patient with CAN 
HEART RATE RESPONSE TO DEEP BREATHING  
R-R variation with respiration depends on parasympathetic 
system. The patient is made to lie supine comfortably and asked to 
breathe in and out deeply at a rate of around 6 breaths per minute. This 
rate is chosen as maximum beat to beat heart rate variation is 
documented at this respiratory rate. Following measures of R-R 
variation are available 
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a. Standard deviation  
b. Mean circular resultant 
c. Expiration to inspiration ratio  
d. Coefficient of variation  
e. Maximum R-R interval minus minimum 
f. Spectral analysis 
HEART RATE RESPONSE TO STANDING  
Heart rate variation from supine to standing is mediated via 
vagus. 
In normal healthy individuals the maximum heart rate is achieved 
at about 15
th
 beat after standing. Maximum relative decrease in heart 
rate is achieved at about 30
th
 beat after standing. In patients with CAN 
this response is very slow. 
Patient is made to lie down quietly and his ECG is recorded. Then 
he is made to stand and ECG tracings are monitored continuously. The 
30:15 ratio i.e., the ratio of maximum R-R @ 30
th
 beat and the minimum 
R-R at 15
th
 beat after standing is calculated. Ziegler et al was the one 
who redefined 30-15 ratio. According to him longest R-R occurring 
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between 20-40 and shortest R-R during 5-25 beats is taken and the ratio 
is calculated.(75) 
VALSALVA MANEUVER  
During straining phase of valsalva maneuver reflex increase in 
heart rate and peripheral vasoconstriction occurs first. This is followed 
by over shoot increase in blood pressure and decrease in heart rate 
occurs after the strain is released. This reflex response occurs by 
alternate stimulation of parasympathetic and sympathetic nervous 
system. In diabetics with autonomic neuropathy the above reflex is 
deranged. In these patients during the straining phase there is a blunted 
heart rate and blood pressure response. Also after release of strain there 
is a slow recovery. 
During the procedure of valsalva patient is made to lie supine, 
connected to ECG recorder. Patient is made to forcibly exhale for 15 
seconds with an open glottis against a resistance of 40 mmHg. This 
produces a sudden but transient augmentation of intra abdominal and 
intra thoracic pressures.  
Patients with lens dislocation, proliferative diabetic retinopathy 
have a risk of intra ocular hemorrhage.  
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There are 4 phases in valsalva (76) 
 Response Systolic BP Pulse rate 
Phase I Onset of strain  Increase Stable 
Phase II Continued strain Decrease Increase 
Phase III Release Decrease Stable 
Phase IV Recovery Increase Decrease 
 
Stage I and III are short transient phases. 
Stage II and IV are significant phases. 
Stage I: with the initial straining the intra thoracic pressure increases 
squeezing the blood from pulmonary circulation into left atrium. This 
produces a transient increase in blood pressure. 
Stage II: with ongoing strain and raising intra thoracic pressure the 
venous return to the heart is decreased. This decreases cardiac output 
producing increased sympathetic activation causing reflex tachycardia 
and increase in peripheral vascular resistance. 
Stage III: With the release of strain the  inflow of blood into pulmonary 
circulation increases but the outflow of blood from left ventricle is also 
decreased so there is a transient decrease in blood pressure. 
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Stage IV: recover from strain augments the venous return further 
producing an increase in blood pressure which reflexly stimulates the 
baro receptors via vagus producing a fall in heart rate.  
Valsalva rate is calculated as the ratio of  maximum R-R interval 
after the straining which reflects the reflex bradycardia to minimum R-R 
interval during the straining which reflects the reflex tachycardia 
response. 
Valsalva maneuver is the single best method for longitudinal 
monitoring of the progression of autonomic dysreflexia. In diabetics as 
it assesses both sympathetic and parasympathetic nerve functions 
simultaneously. 
HRV test performance- summary (84) 
 E:I ratio Valsalva  ratio 30:15 ratio 
Sensitivity 0.93 0.98 0.93 
Specificity 0.93 0.91 0.93 
Positive predictive value  0.93 0.91 0.92 
Positive predictive value  0.94 0.98 0.93 
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ASSESSMENT OF SYMPATHETIC FUNCTION  
SYSTOLIC BLOOD PRESSURE RESPONSE TO STANDING 
In healthy individuals, there is a peripheral pooling of blood in 
lower limb vessels producing a decreased venous return and cardiac 
output. This produces a decrease in cardiac output and fall in blood 
pressure. This stimulates baroreceptors via sympathetics producing a 
reflex raise in heart rate and peripheral vasoconstriction.reduction in 
systolic BP is less than 10mmHg in 30sec in normal persons.  
In diabetics with autonomic dysreflexia, the compensatory 
mechanism mediated by baroreceptor stimulation is affected producing a 
excess fall in systolic BP. Orthostatic response is considered abnormal 
when systolic BP reduces more than 30 mmHg or diastolic BP reduces 
more than 10 mmHg within 2 min of standing from supine posture.(85) 
American Academy of Neurology has redefined orthostatic 
hypotension as a reduction of systolic BP of more than 20mmHg or 
diastolic BP of more than 10mmHg associated with 
symptomatology.(86) 
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Tilt table testing 
Another standardised method of assessing postural fall in BP is 
passive head tilting. This is a better method as it is not associated with 
contraction of lower limb muscles and peripheral pooling of  blood. 
The patient is made to lie supine in a tilt table and head is 
passively tilted to 60 degree. This tilt is maintained for 10-60 min or 
until he develops postural symptoms. Just as in standing response, 
compensatory mechanisms  gets activated and a reflex raise in heart rate  
and BP fall as outlined before is the response . 
BLOOD PRESSURE RESPONSE TO SUSTAINED HAND GRIP 
By using a hand grip dynamometer, a handgrip that is about 30% 
of maximum isometric voluntary contraction is maintained for 5 min. 
diastolic BP before the start of the procedure and just before the release 
of hand grip is measured. The difference between the two is calculated. 
This reflex is mediated by sympathetic system. 
A increase in diastolic BP of more than 16 mmHg is normal. An 
increase of less than 10mmHg is considered abnormal response. 
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Frequency domain analysis 
The above methods described for HRV assessment falls under the 
category of time domain analysis. HRV can also be analysed by power 
spectral analysis of R-R sequences for a short period or on a 24 hour 
ECG. This is called frequency domain analysis. The advantage in this 
method is it needs minimum patient participation as against the previous 
conventional methods. Heart rate variation in various frequency is 
analysed. The power spectrum bands of heart rate is divided into two 
frequency bands. 
a. Low frequency band  – 0.04-0.15Hz   - this is influenced by 
sympathetic and parasympathetic activity. 
b. High frequency band – 0.15-0.4Hz  - this is influenced by 
parasympathetic activity  
Various studies have analysed the time domain and frequency 
domain analysis and have documented a strong association between the 
two methods by Freeman et al and Howorka et al.(77,78) 
In Spectral analysis, succeeding sequence of R-R intervals are 
decomposed. By various mathematical calculations sinusoidal functions 
of various amplitudes and frequencies are calculated and their 
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summation is computed. The power spectrum of HRV is obtained which 
reflects amplitudes of heart rate variations at different frequencies 
studied. 
HRV power spectrum shows three peaks : 
1. Very low frequency (less than 0.04Hz)- reflects fluctuation in 
vasomotor tone – mediated by sympathetic  
2. Low frequency zone(0.1 Hz)- represents waves produced by 
baroreceptor reflex –mediated by both parasympathetic and 
sympathetic 
3. High frequency zone(0.25Hz)- reflects respiratory activity- 
mediated by parasympathetic system. 
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Sensitive HRV index in diabetic patients for assessing autonomic 
dysfunction is spectral analysis in low frequency band. Among Ewings 
battery of tests, HRV to deep breathing, valsalva and 30:15 ratio to 
standing are sensitive indicators. 
Spectral analysis can be used in analysing a 24 hour HRV. In 
normal individuals low frequency power spectrum mediated by 
sympathetic predominates during the day and a predominance of high 
frequency component in the night as it is mediated by vagus. 
In diabetics with autonomic dysfunction, this circadian variation 
is lost. Also they display a decrease in absolute values of both high and 
low frequency oscillations. Earliest indicator of CAN is decrease in the 
nocturnal increase of vagal dominated high frequency band. 
EWINGS BATTERY OF TEST – INTERPRETATION  
TEST normal Borderline  abnormal 
                                                    Parasympathetic function 
Valsalva ratio >=1.21 1.11- 1.20 <= 1.10 
E:I ratio  >=15 11-14 <=10 
30:15 ratio >=1.04 1.01-1.03 <=1 
                                                    Sympathetic function  
Systolic BP fall on 
standing 
<=10 mmHg 11-29 >=30mmHg 
Diastolic BP increase to 
sustained hand grip  
>=16mmHg 11-15 <=10mmHg 
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Categories 
I . normal – all test normal or 1parasympathetic  test is borderline  
II. early- one of the 3 parasympathetic test abnormal or 2 test 
borderline  
III.  definite – 2 or more parasympathetic test abnormal  
IV. severe - 2 or more parasympathetic test abnormal  + one of the 
sympathetic test abnormal  
V. atypical – not fitting into any of the above pattern  
OTHER TESTS OF CAN  
Spontaneous Baroreflex Testing 
Based on servo plethismomanometry measures this technique beat 
to beat blood pressure. By this technique neural modulation of sinus 
node by baroreceptor reflex mechanism is measured. 
Cardiac Radionuclide Imaging 
Radio nucleotide scan uses two norepinephrine  analogues  
a. MIBG  
b. hydroxyephedrine(HED) 
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MIBG uptake by the myocardium is reduced in patients with 
CAN. More sensitive method than conventional autonomic reflex 
testing. The uptake defects in early CAN occurs mostly in left 
ventricular infero posterior segments.  
HED uptake and retention is also reduced in diabetic patients with 
CAN. In advanced CAN there is a heterogenous retention of HED by  
the myocardium. Proximal segments of myocardium shows excess 
retention whereas distal segments shows attenuation. This myocardial 
dysinnervation – proximal hyperinnervation and distal denervation 
produces highly electrically unstable myocardium  predisposing to 
arrhythmias. 
MICRO NEUROGRAPHY  
Electrical activity produced by sympathetic nerves innervating 
peroneal, tibial or radial muscle is recorded and the sympathetic burst is 
mapped. This sympathetic neurogram produces a characteristic shape 
which is analysed. Automated sympathetic neurograms assessing beat to 
beat variations are available. 
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CURRENT GUIDELINES FOR CAN TESTING  
San Antonio Conference held 1998 and 1992 jointly with ADA 
and AAN has published a consensus statement regarding autonomic 
testing in diabetes. The following test are recommended: 
For parasympathetic function – heart rate response to  
1. deep breathing  
2. standing  
3. Valsalva  maneuver  
Sympathetic function testing recommended 
Blood pressure response  
1. To standing or passive tilting 
2. To sustained hand grip 
The consensus panel further staged cardiac dysreflexia as follows  
1. Early stage: Abnormal heart rate variation to deep breathing alone  
2. Intermediate stage: Abnormal valsalva response  
3. Severe: Presence of orthostatic hypotension  
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Candidates to be screened for CAN - ADA recommendations 
1. All type 2 diabetics at diagnosis and if normal to be screened 
annually 
2. All type 1 diabetics at 5 years after diagnosis and annually 
thereafter 
Safety of the testing procedure  
Some procedures carry a small theoretical risk. Valsalva increases 
intra ocular intra thoracic and intracranial pressures and has a small risk 
on intra ocular hemorrhage in preoliferative diabetic retinopathy and 
lens dislocation. 
DCCT has evaluated 1441 type 1 diabetic patients  over 6.5 years 
with cardiac autonomic function testing without any adverse 
complications (79) 
These test when used by properly trained individual is safe and 
effective.  
  
53 
MANAGEMENT OF CARDIAC AUTONOMIC DYSREFLEXIA: 
1. Aid Tight Glycemic Control  
Long term poor blood sugar control is the prime risk factor which 
increases the incidence and progression of cardiac autonomic 
neuropathy. Mustonen et al documented the association between poor 
glycemic control and progression of autonomic dysfunction in a 4 year  
follow up study conducted in a type 2 diabetics(80) 
DCCT has showed that type 1 diabetics with intensive blood 
sugar control, has less incidence in the development of abnormal HRV.  
Intensive insulin therapy has been effective in preventing the 
complications in both type 1 and type 2 diabetics. 
Delay in treatment of diabetes worsens the autonomic neuropathy.  
Tight blood sugar control produces stabilization and prevents 
further worsening of neuropathy but reversal is less likely.  
Hypoglycemic unawareness is more among the individuals with 
cardiac autonomic neuropathy which warrants regular, more vigilant 
glycemic monitoring.  
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2. To Initiate Treatment For CAN 
Early identification of autonomic dysreflexia in diabetics helps in 
early initiation of  
a. Pharmacological and non pharmacological treatment for BP and 
dyslipidemia 
b. ACE and aspirin prophylaxis  
c. Cessation of alcohol and tobacco intake  
d. Good nutrition  
e. Antioxidants like alpha lipoic acid has promising results in 
slowing the progression in some studies.Vitamin has also shown 
some improvement but needs further testing  
f. Cardioselective beta blockers by antagonizing sympathetic 
activity has shown to improve parasympathetic tone. Metaprolol 
given in type I diabetics has shown improved autonomic function 
g. Aldose redutase inhibitors eg., sorbinil and eparlestat have 
demonstrated improved MIBG uptake in patients with mild CAN. 
It has no role in advanced disease. 
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3. To Recommend Desired Adherance to  Diet And Exercise 
Regimen  
Recently a small study report has shown not only diabetes also 
prediabetes is associated with diabetic neuropathy  
Preventive measures, lifestyle modifications, regular exercise has 
a definite role in the prevention of micro and macro vascular 
complications. 
CAN testing would enable the physician to explain and intensify 
non pharmacological therapies among diabetics. 
CAN testing also enable physician for a proper exercise regimen 
that would suit the patient. 
4. Anaesthetic Implications of CAN Testing 
Preoperative cardiovascular autonomic testing in diabetics 
enables the anaesthesiologist to fore see the intra operative 
complications especially during general anaesthesia as these patients 
have a increased fall of heart rate and blood pressure during induction of 
anaesthesia. 
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Also these patients have reduced ventilatory drive during the post 
operative period. Also the need for vasopressors is more in these 
patients with significant cardiac autonomic neuropathy.  
5. Treatment for Orthostatic Symptoms  
A. Non Pharmacological Measures: 
1. to increase the intake of water  
2. lower extremity elastic stockings 
3. frequent small feeds to prevent post prandial hypotension  
4. avoid straining as raised intra abdominal and intrathoracic 
pressures impedes venous return 
5. physical maneuvers like squatting, leg crossing increased 
cardiac filling   and stroke volume  
6. checkout for drugs that aggravate hypotension eg., TCAs, 
phenothiazides  
B. Pharmocological Measures  
1.  Midodrine 
- selective, peripheral A 1 receptor agonist  
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- only agent approved by FDA for the treatment of 
orthostatic hypotension  
 - dose 2.5 – 10 mg three times a day 
- fewer CNS side effects as it does not cross the blood brain 
barrier  
- adverse effects- pruritis, paresthesias, urinary retention, 
piloerection, supine hypertension (81) 
2. Fludrocortisone acetate  
- synthetic mineralocorticoid  
- long plasma half life  
- lncreases the sensitivity of the blood vessels to circulating 
catecholamines  
- increases plasma expansion  
- dose 0.05 mg  @ bed time titrate slowly to a maximum 
dose of 0.2 mg/day 
- adverse effects –supine hypertension , hypokalemia, fluid 
retention, hypomagnesemia,  congestive cardiac failure (82) 
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3. Erythropoietin  
- increases RBC mass, blood volume, mediates neuro 
humoral effects on blood vessel wall and regulates the 
vascular tone by mediating interaction of haemoglobin and 
nitric oxide.  
- dose 25- 75 units per kg body wt three times a week sc/iv 
until patient achieves normal haematocrit. Maintain on a 
low dose of 25 units/kg thrice a week (82) 
4. Nonselective B blockers  
- these drugs blocks the B2 receptors of blood vessel which 
mediate vaso dilatation and thereby facilitates unopposed 
alpha receptor mediator vasoconstriction  
- limited role for these drugs (82) 
5. Clonidine 
- Alpha 2 blocker  
- central sympatholytic activity  
- in patients with severe CAN the central sympathetic 
efferent activation is blunted and clonidine produces 
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increase in venous return without affecting peripheral 
vascular resistance  
– limited use due to serious adverse effects (82) 
6. Somatostatin analogues  
- these drugs inhibit vasoactive peptides released from GIT, 
increases splanchnic vasoconstriction , venous return and 
cardiac output 
 - dose 25-200 micrograms /day 
- development of severe hypertension precludes its use  
7. Pyridostigmine bromide  
- cholinesterase inhibitor  
- increases ganglionic transmission without affecting supine 
hypertension (83) 
8. Fluoxetine  
- SSRI has shown improvement in symptoms in patients with 
Parkinson disease  
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Ansiscope (85) 
 
 
Ansiscope is an electronic instrument which measure sympathetic 
and para sympathetic  activity with each heart beat. Dysautonomia is 
defined by lack of concordance between the parasympathetic- 
sympathetic system. The measurement is made in  10- 15 minutes. The 
patient is made to lie in the supine position comfortably. The electrodes 
are connected to the patient and the individual is made to lie in  rest. 
The ansiscope counts 571 R-R intervals. For this a good ECG 
signal must be obtained. The R of the QRS peak must be well defined.  
The ansiscope measures the coupling between the autonomic 
nervous system. It measures the amount of time the two system not 
working in concordance with in the count of 571 R-R interval and this 
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sympatho vagal imbalance is given as percentage value which implies 
the proportion of time the two systems are decoupled.  
The heart rate variability is the underlying mechanism which is 
measured. It is a mathematical instrument which works under the 
physical principle of scale covariance law.  
At the end of measurement the ansiscope displays the following 
two information  
A. the percentage of  autonomic dysfunction  
B. patient classification as healthy , early , late , advanced and most 
advanced based on the percentage of dysautonomia  
Advantages  
1. quick measure of cardiac dysautonomia 
2. time advantage  
3. non invasive  
4. patient friendly 
5. does not involve patient effort/ maneuver 
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6. does not involve tedious calculations as conventional autonomic 
scoring  
7. reproducible  
8. no recurring expenditure  
9. helps in the monitoring of therapy 
10. no other device available till now 
11. portable 
Disadvantages 
1. initial expenditure  
2. not standardized  
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MATERIALS AND METHODS 
 
PLACE OF STUDY 
Department of General Medicine – OP and IP  patients, Govt  
Stanley Medical College and Hospital, Chennai. 
DURATION 
 FEB 2013 – DEC 2013 
STUDY DESIGN 
 PROSPECTIVE OBSERVATIONAL STUDY 
PATIENT SELECTION 
TYPE 2 DIABETIC PATIENTS  
EXCLUSION CRITERIA 
Patients with the following are excluded from the study  
1. End organ damage in the form of  coronary artery disease,CCF, 
2. Patients on anti depressants, sympathetic  blockers, vasodilators, 
anti histamines, diuretics, aspirin 
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3. Age more than 70 
4. Proliferative diabetic retinopathy  
5. Alcoholics  
METHODOLOGY 
Patients with Type 2 diabetes in both OP AND IP basis from FEB 
2013 to DEC 2014 were included in the study. Patients were subjected 
to symptom analysis, clinical examination and laboratory investigations.  
Eligible cohorts were subjected to standard autonomic testing and 
testing with ANSiscope. 
Standard autonomic testing includes  
Assessing heart rate variability with  
        1.  deep breathing 
        2.  valsalva  
        3.  supine to standing position 
  Assessing blood pressure variability with  
1.  supine to standing 
65 
Procedure  
Resting ECG was taken for all the patients. Individuals in the 
study group were subjected to ECG recordings. Preferred lead is lead II. 
Subjects were made to lie supine comfortably. Then they were 
asked to take deep breathe evenly at the rate of 6 breaths per minute i.e., 
5 seconds for inspiration and 5 seconds for expiration. A continuous 
ECG was recorded for one minute. The maximum and minimum R-R 
interval during the respiratory cycle was calculated and converted to 
beats per minute. The difference between the two and heart rate 
variation of less than 10 beats per minute was  taken as abnormal. Then 
the patient was allowed to lie quietly for another 5 minutes. The patient 
was made to exhale forcibly into the mouth piece of manometer 
sustaining a pressure of 40 mmHg for about 15 seconds and the ECG 
was recorded continuously. The patient was made to stop the maneuver 
and the ECG was further recorded post maneuver. The ratio of shortest 
R-R interval during the maneuver and the longest R-R post valsalva was 
calculated. A ratio less than 1.10 was considered abnormal. Again the 
patient was made to lie supine quietly. After about 5 minute with 
continuous monitoring the patient was made to stand. The R-R internal 
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at 15
th
beat and 30
th
  beat was calculated. The 30:15 ratio of less than 
1.00 was considered abnormal. 
For the assessment of the sympathetic function, patient was made 
to lie down and his BP recorded. Then he was made to stand up and 
again BP measurement was made 2 minutes after standing. A fall of 
systolic Blood Pressure more than 30 mmHg was considered abnormal. 
Based on the above standard testing patients with 2 or more abnormal 
test were  classified as definite, one of the three heart rate variability test 
abnormal were classified as early. When individuals with 
parasympathetic dysfunction along with significant BP fall were 
classified as severe CAN as per Ewings et al. 
For testing of patients with ansiscope, patients were instructed to 
lie supine comfortably. The electrodes were connected and after 
obtaining good ECG signal the test was commenced. At the end of count 
of 571 R-R intervals the instrument display the presence/absence of 
CAN and the severity. 
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OBSERVATIONS AND DATA ANALYSIS 
 
1. SEX DISTRIBUTION  
Sex Frequency % of Study Group 
MALE  30 35.7 
FEMALE  54 64.3 
TOTAL  84 100 
 
2. CAN POSITIVITY  
CAN Ansiscope Conventional 
Frequency Percentage Frequency Percentage 
Yes  70 83.3 75 89.3 
No 14 16.7 9 10.7 
TOTAL 84 100 84 100 
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3. SEVERITY OF CAN  
 Ansiscope Conventional 
Frequency Percentage Frequency Percentage 
EARLY  9 12.8 19 25.0 
LATE  47 67.1 53 69.7 
ADVANCED 14 20 4 5.26 
TOTAL 70 100 76 100 
 
4. VALSALVA RATIO 
 Frequency Percentage 
NORMAL  16 19 
BORDERLINE 45 53.6 
ABNORMAL 23 27.4 
TOTAL 84 100 
 
5. E:I RATIO 
 Frequency Percentage 
NORMAL  9 10.7 
BORDERLINE 15 17.9 
ABNORMAL 60 71.4 
TOTAL 84 100 
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6. 30:15 RATIO 
 Frequency Percentage 
NORMAL  11 13.1 
BORDERLINE 20 23.8 
ABNORMAL 53 63.1 
TOTAL 84 100 
 
7. ORTHOSTATIC HYPOTENSION  
 Frequency Percentage 
NORMAL  59 70.2 
BORDERLINE 21 25.0 
ABNORMAL 4 4.8 
TOTAL 84 100 
 
8. SENSITIVITY AND SPECIFICITY OF THE HRV TEST  
Test Sensitivity (%) Specificity (%) 
VALSALVA RATIO 86.7 66.7 
E:I RATIO 92 33.3 
30:15 RATIO  92 55.6 
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9. ASSOCIATION OF VARIOUS PARAMETERS WITH CAN  
Parameter % of  
subjects 
Prevalence of CAN p Value 
Conven-
tional 
Ansiscope Conven-
tional 
Ansiscope 
SMOKERS 15.5% 100% 92.3% 0.384 0.58 
HYPERTENSION  42.9% 91.9% 86.1% 0.799 0.761 
PERIPHERAL 
NEUROPATHY 
32.1% 96.3% 92.6% 0.293 0.210 
DURATION OF 
DIABETES 
 
a. at diagnosis  19% 81.2% 68.8% 0.344 0.106 
b.1-5 years  59.5% 88% 82% 
c.>5 years  21.5% 100% 100% 
UNAWARE 75% 93.7% 85.7% 0.039 0.049 
POOR SUGAR 
CONTROL 
33.33% 100% 96.4% 0.026 0.029 
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RESULTS 
 
1. Among the total 84 individuals studied 64.3 % were females and 
35.7 % were males. 
2. A total of 15.5%(13 persons) were smokers and among them 
92.3%(12 persons) and about 100% (13 people) were found to 
have cardiac autonomic neuropathy by ansiscope and 
conventional methods respectively.  
3. 27 subjects  i.e. 32% were found to have peripheral neuropathy by 
clinical testing and among  them 92.6% (25 persons) tested 
positive for autonomic neuropathy by ansiscope and 96.3% (26 
persons ) by conventional method  
4. 36 subjects (42.9%) of the study population were hypertensive 
and of them 31 people(86.1%) and 33 people (91.7%) tested 
positive for autonomic dysfunction by ansiscope and conventional 
method respectively. 
5.  Of the 84 study subjects 63 (75%) people were not aware of the 
complications related to diabetes. In them 54 subjects(85.7% ) 
and 59 subjects(93.7%) tested positive for cardiac autonomic 
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neuropathy by ansiscope and conventional methods respectively. 
This association is found to be statistically significant. 
6. A total of 16 subjects (19%) were examined at diagnosis. Among 
them 11 individuals 68.8% were CAN positive by ansiscope and 
81.2 % (13 subjects) by conventional method. 
7. Of the 84 individuals 50 individuals were diabetic for a duration 
1-5 years. Among them 82% (41 individuals) and 88%(44 
subjects) tested positive for autonomic dysfunction by ansiscope 
and conventional method respectively.  
8. Of the 18 subjects who were diabetic for more than 5 years, were 
tested 100% positive for autonomic dysfunction by both the 
methods.  
9. 28 individuals had poor glycemic control. All individuals with 
poor glycemic control tested positive for cardiac autonomic 
dysfunction by conventional method and 96.4% (27 individuals) 
tested positive by ansiscope. This association is statistically 
significant. 
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10.  Of the 84 subjects tested 27.4% (23 individuals) had abnormal 
valsalva ratio. 71.4% (60 individuals) ha d abnormal inspiratory 
and expiratory ratio. 63.1% (53 individuals) had abnormal 30:15 
ratio. And 4 individuals (4.8%) had significant abnormal 
orthostatic hypotension.  
11. 12.9% of the individuals had tested ‘early’ dysfunction by 
ansiscope. 67.1 % had ‘late’ and 20% were categorized as 
‘advanced’ by ansiscope testing. 
12. 25% individuals had ‘early’,69.7% had ‘definite’ and 5.3% had 
‘advanced’ cardiac autonomic dysfunction.  
13. Sensitivity and specifity of the individual test are as follows  
Valsalva       -  86.7% and 66.7% 
E: I ratio       -  92% and 33.3% 
30:15 ratio   -  92% and 55.6% respectively.  
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DISCUSSION 
 
This study was done to assess the prevalence of cardiac 
autonomic dysfunction in Type 2 diabetics by ansiscope and 
conventional methods which assess the heart rate variability.  
The prevalence rate was 83.3% and 89.3% by ansiscope and 
conventional methods respectively.  
Our study included diabetics of less than one year as ‘at 
diagnosis’. 
‘At diagnosis’ 68.8% were CAN positive by ansiscope and 81.2 
% by conventional method. In individuals with a duration 1-5 years,  
82% and 88% tested positive for autonomic dysfunction by ansiscope 
and conventional method respectively. Diabetics for more than 5 years, 
were tested 100% positive for autonomic dysfunction by either of the 
methods.   
Khandellwal E et al has assessed the evidence of CAN using 
Ewing’s criteria as 79%. Using the same criteria Ramavat manish R et al 
concluded   the prevalence of CAN around 51.9%. 
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Viveka P Jyotsna et al  studied the prevalence of CAN in type 2 
individuals at diagnosis and found the rate of cardiac dysfunction as 
71% (86-88). 
In the present study though there is an increased percentage 
positivity of Cardiac Autonomic Dysfunction in individuals with 
smoking, peripheral neuropathy, duration of diabetes we did not find 
any significant association. In our study there is a significant association 
of CAN positivity in individuals who were unaware of the 
complications of diabetes. 
There is a significant positive association of cardiac autonomic 
dysreflexia in individuals with poor glycemic control in our study. All 
individuals with poor glycemic control tested positive for Cardiac 
Autonomic Dysfunction by conventional method and 96.4% tested 
positive by ansiscope.  
EURO DIAB study has found that the incidence of autonomic 
neuropathy is associated with poor glycemic control.  
STENO TYPE 2 trial has followed up intensively controlled 
diabetics for 8 years and documented a reduced rate of progression of 
autonomic neuropathy.  
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DCCT research group had shown that intensive therapy for 
diabetics decreases the rate of progression and delays the development 
of autonomic dysfunction. 
In our study we have found the heart rate variation with E:I ratio 
and 30:15 ratio is 92% and is found more sensitive compared to other 
methods.  
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CONCLUSION 
 
The prevalence of cardiac autonomic neuropathy is extremely 
high among diabetics as shown in our study. Most  diabetic patients  
have significant autonomic dysreflexia even at diagnosis of diabetes. 
Cardiac autonomic neuropathy is the single important factor which 
predicts the 5 year mortality rate among diabetics. Poor blood sugar 
control is significantly associated with CAN and is the single best factor 
which determines the rate of progression as cited in our study. Also 
individuals who are unaware of the complications of diabetes have 
shown a significant association with autonomic dysreflexia. Early 
screening, early diagnosis, proper education of patients and strict 
glycemic control   help in the arrest of progression of Cardiac 
Autonomic Neuropathy in Type 2 diabetic population. 
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PROFORMA 
 
• NAME :         SL. NO: 
  
• AGE /SEX:  
• OCCUPATION: 
• ADDRESS WITH CONTACT NUMBER:  
 
• IP/OP NO:  
• DATE OF ADMISSION:  
• DATE OF DISCHARGE:  
HISTORY: 
Duration of diabetes  
H/o chest pain , palpitations, syncope,dyspnoea,dizziness 
H/o alcohol , smoking 
Hypertension  
Awareness of the disease and its complications 
Physical examination 
Sensorium  
Pallor 
Pedal edema 
BP:                          PR: 
CVS - 
RS - 
P/A -  
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CNS - 
 
INVESTIGATIONS 
CBC –  TC,DC,ESR 
HB, PLATELETS 
BLOOD SUGAR   
BLOOD UREA, SERUM CREATININE 
TESTING FOR PERIPHERAL NEUROPATHY – VIBRATION 
AND 10 G MONOFILAMENT 
URINE ROUTINE EXAMINATION 
ECG 
CARDIOVASCULAR REFLEX TESTS  
 HEART RATE RESPONSE TO DEEP BREATHING, 
VALSALVA,STANDING  
 BLOOD PRESSURE RESPONSE TO HANDGRIP AND 
STANDING  
NON INVASIVE TESTING USING ANSISCOPE 
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CONSENT FORM 
1) I AGREE TO PARTICIPATE IN STUDY TITLED 
“PREVALENCE OF CARDIAC AUTONOMIC 
NEUROPATHY IN TYPE 2 DIABETIC PATIENTS”  
2)   I CONFIRM THAT I HAVE BEEN TOLD ABOUT THIS 
STUDY IN MY MOTHER TONGUE & HAVE HAD THE 
OPPURTUNITY TO ASK QUESTIONS 
3) I UNDERSTAND THAT MY PARTIPATION IS VOLUNTERY 
& I MAY REFUSE TO PARTICIPATE AT ANY TIME 
WITHOUT GIVING ANY REASON AND  WITHOUT 
AFFECTING MY BENEFITS. 
4) I AGREE NOT TO RESTRICT THE USE OF ANY DATE OR 
RESULTS THAT ARISE FROM THE STUDY 
5)  I AGREE TO UNDERGO CLINICAL AUTONOMIC TESTING  
 
 NAME OF THE PARTICIPANT: 
SIGN/THUMB PRINT     INVESTIGATOR 
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S.No. Name Age Sex Smoke Years HT Peri neuro Aware Control Ansisc Sev Vals EI ratio 30/15 st ortho hyp Conv Sev
1 munusamy 37 1 2 1 2 2 2 1 2 n n n 2 2
2 thiyaga 59 1 2 4 2 2 2 1 1 1 2 2 1 1 1 1
3 amutha 58 2 2 2 2 2 2 2 1 2 2 3 3 1 1 2
4 sivagami 50 2 2 3 1 2 2 2 1 2 2 3 3 2 1 2
5 muniammal 50 2 2 1 2 2 1 1 2 1 2 1 1 2
6 shanthi 48 2 2 1 1 2 1 1 2 2 2 1 1 1 1
7 razia 47 2 2 3 1 2 2 1 1 2 3 3 2 1 1 2
8 bhagyam 61 2 2 6 1 1 2 2 1 2 3 3 2 1 1 2
9 krishnaveni 60 2 2 5 2 2 2 1 1 3 3 3 3 3 1 3
10 surya narayanan 70 2 2 5 2 1 1 1 1 2 1 3 3 1 1 2
11 mani 60 1 2 1 2 2 2 1 1 3 3 3 3 2 1 2
12 sherifa 49 2 2 0 2 2 2 1 1 2 2 3 3 1 1 2
13 maheswari 50 2 2 2 1 2 2 2 1 2 2 3 3 1 1 2
14 kousiya begum 43 2 2 2 2 1 2 2 1 3 3 3 3 2 1 2
15 shanmugam 60 1 1 7 2 2 1 1 1 2 2 3 3 1 1 2
16 subramani 59 1 1 7 1 2 1 1 1 1 2 3 1 1 1 1
17 sujatha 38 2 2 2 2 2 1 1 1 2 2 3 3 1 1 2
18 rajendiram 49 1 2 5 1 2 1 1 1 1 2 3 3 1 1 2
19 kala 35 2 2 0 2 2 1 1 2 1 2 1 1 2
20 vasudevan 49 1 2 6 1 1 2 1 1 2 1 2 3 1 1 1
21 robert 49 1 1 15 1 2 1 2 1 2 3 3 2 1 1 2
22 alima bee 51 2 2 1 2 2 2 2 1 1 2 3 3 1 1 2
23 subair 65 2 2 2 1 1 2 2 1 2 3 3 3 2 1 2
24 bhoopalam 71 1 2 12 2 1 1 1 1 2 2 3 3 1 1 2
25 elizabeth 40 2 2 5 1 1 2 2 1 2 3 3 2 1 1 2
26 srinivasan 44 1 2 2 2 1 1 1 1 1 1 3 1 1 1 1
27 pachaiappan 61 1 2 2 1 1 2 1 1 2 3 3 2 1 1 2
28 rosemary 45 2 2 7 2 1 2 2 1 2 3 1 3 2 1 2
29 anandavalli 45 2 2 3 2 1 2 2 1 2 2 3 3 1 1 2
30 kuppu 40 2 2 3 2 2 1 1 1 2 1 1 3 1 2
31 manonmani 53 2 2 3 1 2 2 1 1 1 2 1 2 1 1 1
32 samiadiyal 48 2 2 7 1 1 1 2 1 3 1 3 3 1 1 2
33 subramani 43 1 2 3 1 2 1 1 2 2 1 1 1 2
34 bhoopalan 71 1 2 4 1 1 2 1 1 2 1 3 3 2 1 2
35 muralidharam 44 1 1 7 2 2 2 1 1 2 2 3 3 1 1 2
36 mahalakshmi 44 2 2 2 1 1 2 2 1 3 3 3 2 1 1 2
37 nagaraj 39 1 1 1 2 2 2 2 2 2 1 2 1 1 1
38 krishnan 56 1 2 5 2 2 2 1 1 1 1 2 2 1 1 1
39 arun 28 1 1 0 2 2 2 1 1 2 2 3 3 1 1 2
40 vasanthi 53 2 2 0 1 1 2 1 1 2 2 3 3 1 1 2
41 ahmed 52 1 1 0 2 2 2 2 1 2 2 3 3 1 1 2
42 meenal 32 2 2 0 2 2 2 1 1 1 2 1 3 1 1 1
43 raman 44 1 1 3 2 2 2 2 1 2 2 3 3 1 1 2
44 asirvatham 48 2 2 2 1 1 2 1 1 2 2 3 3 2 2 2
45 selvi 47 2 2 4 2 2 2 1 1 2 3 3 3 1 1 2
46 logeswari 35 2 2 3 1 2 2 1 2 1 3 1 1 1 1
47 balaraman 65 1 1 5 1 2 2 2 1 2 2 3 3 1 1 2
48 sarawwathy 56 2 2 10 2 2 2 1 1 2 2 3 3 2 1 2
49 vasuki 38 2 2 2 2 1 2 1 2 2 1 2 1 1 1
50 sukuna 51 2 2 4 1 1 2 1 1 3 3 3 3 2 1 2
51 meenal 60 2 2 3 2 2 2 2 1 1 2 3 2 2 1 1
52 padmavathy 70 2 2 10 2 2 1 1 1 3 3 3 2 3 1 3
53 nagaraj 41 1 1 0 2 2 2 1 1 3 2 3 3 2 1 2
54 selvam 50 1 2 0 2 2 2 1 1 3 3 3 3 3 1 3
55 etiyappan 41 1 2 6 2 2 2 2 1 3 3 3 2 2 1 2
56 rajeshwari 58 2 2 5 1 1 2 1 1 2 2 3 3 1 1 2
57 valli 54 2 2 5 2 2 1 1 1 2 2 3 3 2 1 2
58 kamalam 55 2 2 4 2 2 1 1 1 2 2 2 3 1 1 1
59 rajan 45 1 2 0 2 2 2 2 1 2 1 2 2 1 1 2
60 kuppuraj 47 1 2 0 1 2 2 1 2 1 1 2 1 2
61 meenal 60 2 2 3 2 2 2 2 1 2 1 3 3 1 1 2
62 selvi 47 2 2 0 1 2 2 2 1 2 2 3 3 2 1 2
63 amudha 40 2 2 1 1 2 2 2 1 2 3 3 3 1 1 2
64 kannan 51 1 1 2 1 2 2 1 1 2 2 3 3 2 1 2
65 mariammal 45 2 2 0 2 1 2 1 2 1 2 3 1 1 1
66 devaki 52 2 2 10 2 2 2 1 1 2 2 3 3 1 1 2
67 amudha 47 2 2 1 2 1 2 1 1 2 3 3 3 2 1 2
68 jyothi 42 2 2 5 1 2 2 1 1 3 3 3 3 2 1 2
69 meena 45 2 2 0 1 2 2 1 1 2 2 3 3 1 1 2
70 krishnamoorthy 57 1 2 20 1 1 1 1 1 3 3 3 3 2 1 2
71 chellammal 61 2 2 29 1 1 1 2 1 3 3 3 2 1 1 2
72 kanniappan 34 1 2 4 2 2 2 2 1 3 3 3 3 3 1 3
73 mariappa 63 2 2 5 1 1 2 1 1 2 2 3 3 2 1 2
74 kuppan 60 1 1 10 1 1 2 2 1 2 2 2 3 1 1 1
75 parameswari 42 2 2 3 2 2 2 1 1 2 2 3 3 1 1 2
76 kalyani 55 2 2 11 2 1 1 1 1 2 2 2 3 1 1 1
77 annal 65 2 2 4 2 2 2 1 1 2 2 3 2 1 1 2
78 gomathy 34 2 2 1 2 2 1 1 2 1 2 1 1 2
79 seetha 60 2 2 3 2 2 2 1 1 2 2 3 3 1 1 2
80 rojammal 55 2 2 0 2 2 2 1 2 2 1 2 1 1 1
81 gangammal 55 2 2 8 1 1 2 2 1 2 3 3 3 2 1 2
82 selvi 52 2 2 4 1 2 2 1 2 2 2 1 1 1 1
83 damodaran 45 1 1 0 1 2 2 2 1 2 2 3 2 1 1 1
84 kasiammal 42 2 2 0 2 2 2 1 2 1 2 1 1 2
1-M 1-YES 1-y 1-yes 1- yes 1-yes 1- can +ve 1- early 1 -N 1 -N 1 -N 1 -N 1- can +ve 1- early
2- late 2-BL 2-BL 2-BL 2-BL 2- definit
3- adv 3-abn 3-abn 3-abn 3-abn 3- adv
S.No. Name Age Sex Smoke Years HT Peri neuro Aware Control Ansisc Sev Vals EI ratio 30/15 st ortho hyp Conv Sev
1 munusamy 37 1 2 1 2 2 2 1 2 n n n 2 2
2 thiyaga 59 1 2 4 2 2 2 1 1 1 2 2 1 1 1 1
3 amutha 58 2 2 2 2 2 2 2 1 2 2 3 3 1 1 2
4 sivagami 50 2 2 3 1 2 2 2 1 2 2 3 3 2 1 2
5 muniammal 50 2 2 1 2 2 1 1 2 1 2 1 1 2
6 shanthi 48 2 2 1 1 2 1 1 2 2 2 1 1 1 1
7 razia 47 2 2 3 1 2 2 1 1 2 3 3 2 1 1 2
8 bhagyam 61 2 2 6 1 1 2 2 1 2 3 3 2 1 1 2
9 krishnaveni 60 2 2 5 2 2 2 1 1 3 3 3 3 3 1 3
10 surya narayanan 70 2 2 5 2 1 1 1 1 2 1 3 3 1 1 2
11 mani 60 1 2 1 2 2 2 1 1 3 3 3 3 2 1 2
12 sherifa 49 2 2 0 2 2 2 1 1 2 2 3 3 1 1 2
13 maheswari 50 2 2 2 1 2 2 2 1 2 2 3 3 1 1 2
14 kousiya begum 43 2 2 2 2 1 2 2 1 3 3 3 3 2 1 2
15 shanmugam 60 1 1 7 2 2 1 1 1 2 2 3 3 1 1 2
16 subramani 59 1 1 7 1 2 1 1 1 1 2 3 1 1 1 1
17 sujatha 38 2 2 2 2 2 1 1 1 2 2 3 3 1 1 2
18 rajendiram 49 1 2 5 1 2 1 1 1 1 2 3 3 1 1 2
19 kala 35 2 2 0 2 2 1 1 2 1 2 1 1 2
20 vasudevan 49 1 2 6 1 1 2 1 1 2 1 2 3 1 1 1
21 robert 49 1 1 15 1 2 1 2 1 2 3 3 2 1 1 2
22 alima bee 51 2 2 1 2 2 2 2 1 1 2 3 3 1 1 2
23 subair 65 2 2 2 1 1 2 2 1 2 3 3 3 2 1 2
24 bhoopalam 71 1 2 12 2 1 1 1 1 2 2 3 3 1 1 2
25 elizabeth 40 2 2 5 1 1 2 2 1 2 3 3 2 1 1 2
26 srinivasan 44 1 2 2 2 1 1 1 1 1 1 3 1 1 1 1
27 pachaiappan 61 1 2 2 1 1 2 1 1 2 3 3 2 1 1 2
28 rosemary 45 2 2 7 2 1 2 2 1 2 3 1 3 2 1 2
29 anandavalli 45 2 2 3 2 1 2 2 1 2 2 3 3 1 1 2
30 kuppu 40 2 2 3 2 2 1 1 1 2 1 1 3 1 2
31 manonmani 53 2 2 3 1 2 2 1 1 1 2 1 2 1 1 1
32 samiadiyal 48 2 2 7 1 1 1 2 1 3 1 3 3 1 1 2
33 subramani 43 1 2 3 1 2 1 1 2 2 1 1 1 2
34 bhoopalan 71 1 2 4 1 1 2 1 1 2 1 3 3 2 1 2
35 muralidharam 44 1 1 7 2 2 2 1 1 2 2 3 3 1 1 2
36 mahalakshmi 44 2 2 2 1 1 2 2 1 3 3 3 2 1 1 2
37 nagaraj 39 1 1 1 2 2 2 2 2 2 1 2 1 1 1
38 krishnan 56 1 2 5 2 2 2 1 1 1 1 2 2 1 1 1
39 arun 28 1 1 0 2 2 2 1 1 2 2 3 3 1 1 2
40 vasanthi 53 2 2 0 1 1 2 1 1 2 2 3 3 1 1 2
41 ahmed 52 1 1 0 2 2 2 2 1 2 2 3 3 1 1 2
42 meenal 32 2 2 0 2 2 2 1 1 1 2 1 3 1 1 1
43 raman 44 1 1 3 2 2 2 2 1 2 2 3 3 1 1 2
44 asirvatham 48 2 2 2 1 1 2 1 1 2 2 3 3 2 2 2
45 selvi 47 2 2 4 2 2 2 1 1 2 3 3 3 1 1 2
46 logeswari 35 2 2 3 1 2 2 1 2 1 3 1 1 1 1
47 balaraman 65 1 1 5 1 2 2 2 1 2 2 3 3 1 1 2
48 sarawwathy 56 2 2 10 2 2 2 1 1 2 2 3 3 2 1 2
49 vasuki 38 2 2 2 2 1 2 1 2 2 1 2 1 1 1
50 sukuna 51 2 2 4 1 1 2 1 1 3 3 3 3 2 1 2
51 meenal 60 2 2 3 2 2 2 2 1 1 2 3 2 2 1 1
52 padmavathy 70 2 2 10 2 2 1 1 1 3 3 3 2 3 1 3
53 nagaraj 41 1 1 0 2 2 2 1 1 3 2 3 3 2 1 2
54 selvam 50 1 2 0 2 2 2 1 1 3 3 3 3 3 1 3
55 etiyappan 41 1 2 6 2 2 2 2 1 3 3 3 2 2 1 2
56 rajeshwari 58 2 2 5 1 1 2 1 1 2 2 3 3 1 1 2
57 valli 54 2 2 5 2 2 1 1 1 2 2 3 3 2 1 2
58 kamalam 55 2 2 4 2 2 1 1 1 2 2 2 3 1 1 1
59 rajan 45 1 2 0 2 2 2 2 1 2 1 2 2 1 1 2
60 kuppuraj 47 1 2 0 1 2 2 1 2 1 1 2 1 2
61 meenal 60 2 2 3 2 2 2 2 1 2 1 3 3 1 1 2
62 selvi 47 2 2 0 1 2 2 2 1 2 2 3 3 2 1 2
63 amudha 40 2 2 1 1 2 2 2 1 2 3 3 3 1 1 2
64 kannan 51 1 1 2 1 2 2 1 1 2 2 3 3 2 1 2
65 mariammal 45 2 2 0 2 1 2 1 2 1 2 3 1 1 1
66 devaki 52 2 2 10 2 2 2 1 1 2 2 3 3 1 1 2
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68 jyothi 42 2 2 5 1 2 2 1 1 3 3 3 3 2 1 2
69 meena 45 2 2 0 1 2 2 1 1 2 2 3 3 1 1 2
70 krishnamoorthy 57 1 2 20 1 1 1 1 1 3 3 3 3 2 1 2
71 chellammal 61 2 2 29 1 1 1 2 1 3 3 3 2 1 1 2
72 kanniappan 34 1 2 4 2 2 2 2 1 3 3 3 3 3 1 3
73 mariappa 63 2 2 5 1 1 2 1 1 2 2 3 3 2 1 2
74 kuppan 60 1 1 10 1 1 2 2 1 2 2 2 3 1 1 1
75 parameswari 42 2 2 3 2 2 2 1 1 2 2 3 3 1 1 2
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77 annal 65 2 2 4 2 2 2 1 1 2 2 3 2 1 1 2
78 gomathy 34 2 2 1 2 2 1 1 2 1 2 1 1 2
79 seetha 60 2 2 3 2 2 2 1 1 2 2 3 3 1 1 2
80 rojammal 55 2 2 0 2 2 2 1 2 2 1 2 1 1 1
81 gangammal 55 2 2 8 1 1 2 2 1 2 3 3 3 2 1 2
82 selvi 52 2 2 4 1 2 2 1 2 2 2 1 1 1 1
83 damodaran 45 1 1 0 1 2 2 2 1 2 2 3 2 1 1 1
84 kasiammal 42 2 2 0 2 2 2 1 2 1 2 1 1 2
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10 surya narayanan 70 2 2 5 2 1 1 1 1 2 1 3 3 1 1 2
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18 rajendiram 49 1 2 5 1 2 1 1 1 1 2 3 3 1 1 2
19 kala 35 2 2 0 2 2 1 1 2 1 2 1 1 2
20 vasudevan 49 1 2 6 1 1 2 1 1 2 1 2 3 1 1 1
21 robert 49 1 1 15 1 2 1 2 1 2 3 3 2 1 1 2
22 alima bee 51 2 2 1 2 2 2 2 1 1 2 3 3 1 1 2
23 subair 65 2 2 2 1 1 2 2 1 2 3 3 3 2 1 2
24 bhoopalam 71 1 2 12 2 1 1 1 1 2 2 3 3 1 1 2
25 elizabeth 40 2 2 5 1 1 2 2 1 2 3 3 2 1 1 2
26 srinivasan 44 1 2 2 2 1 1 1 1 1 1 3 1 1 1 1
27 pachaiappan 61 1 2 2 1 1 2 1 1 2 3 3 2 1 1 2
28 rosemary 45 2 2 7 2 1 2 2 1 2 3 1 3 2 1 2
29 anandavalli 45 2 2 3 2 1 2 2 1 2 2 3 3 1 1 2
30 kuppu 40 2 2 3 2 2 1 1 1 2 1 1 3 1 2
31 manonmani 53 2 2 3 1 2 2 1 1 1 2 1 2 1 1 1
32 samiadiyal 48 2 2 7 1 1 1 2 1 3 1 3 3 1 1 2
33 subramani 43 1 2 3 1 2 1 1 2 2 1 1 1 2
34 bhoopalan 71 1 2 4 1 1 2 1 1 2 1 3 3 2 1 2
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37 nagaraj 39 1 1 1 2 2 2 2 2 2 1 2 1 1 1
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46 logeswari 35 2 2 3 1 2 2 1 2 1 3 1 1 1 1
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60 kuppuraj 47 1 2 0 1 2 2 1 2 1 1 2 1 2
61 meenal 60 2 2 3 2 2 2 2 1 2 1 3 3 1 1 2
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64 kannan 51 1 1 2 1 2 2 1 1 2 2 3 3 2 1 2
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